RGRX Depositi SEC - RegeneRx Biopharmaceuticals, Inc.- Relazione annuale, dichiarazione di delega, prospetto informativo

Statistiche di base

CIK

707511

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to RegeneRx Biopharmaceuticals, Inc.

SEC Filings (Chronological Order)

Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.

August 14, 2023	15-12G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-15070 RegeneRx Biopharmaceuticals, Inc. (Exact name of registrant as spe
August 7, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 REGENERX BIOPHARMA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 REGENERX BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-15070 52-1253406 (State or other jurisdiction of incorporation) (C
July 11, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin
July 10, 2023	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 REGENERX BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-15070 52-1253406 (State or other jurisdiction of incorporation) (Comm
July 10, 2023	EX-10.65	15245 Shady Grove Road Exhibit 10.65 15245 Shady Grove Road Suite 470 Rockville, MD 20850 301.208.9191 July 10, 2023 Dear Stockholder: The next few months will represent a transitional change for RegeneRx, as we are moving from a public company to a private one and further paring down operations as we await results from our phase 3 clinical trials in patients with neurotrophic keratitis (NK). As you know, these trials a
July 6, 2023	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 ea181373ex99-1regen.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Schedule 13D with respect to the Common Stock of RegeneRx Biopharmaceuticals, Inc. dated as of July 6, 2023, is, and any amendments thereto signed by such of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule
July 6, 2023	SC 13D/A	RGRX / Regenerx Biopharmaceuticals / Essetifin SPA - AMENDMENT NO. 26 TO SCHEDULE 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 26)* Under the Securities Exchange Act of 1934 RegeneRx Biopharmaceuticals, Inc. (Name of Issuer) Common Stock, Par Value $0.001 per share (Title of Class of Securities) 75886X 10 8 (CUSIP Number) Marino Zigrossi Managing Director Essetifin S.p.A. Via Sudafrica, 20 Rome, RM 00144 Italy +39 06 5427711 (Name, Addre
July 6, 2023	EX-99.2	REGENERX BIOPHARMACEUTICALS, INC. CONVERTIBLE NOTE AND WARRANT PURCHASE AGREEMENT July 3, 2023 TABLE OF CONTENTS Exhibit 2 REGENERX BIOPHARMACEUTICALS, INC. CONVERTIBLE NOTE AND WARRANT PURCHASE AGREEMENT July 3, 2023 TABLE OF CONTENTS PAGE SECTION 1. DEFINITIONS 1 SECTION 2. ISSUANCE AND SALE OF THE SECURITIES 3 2.1 Funding 3 SECTION 3. THE FUNDING 3 3.1 Funding 3 3.2 Deliveries by the Company 4 3.3 Deliveries by the Investor 4 SECTION 4. REPRESENTATIONS, WARRANTIES AND COVENANTS 4 4.1 Representations and W
July 6, 2023	EX-99.3	CONVERTIBLE PROMISSORY NOTE Exhibit 3 THIS CONVERTIBLE PROMISSORY NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF.
July 6, 2023	EX-99.4	REGENERX BIOPHARMACEUTICALS, INC. WARRANT TO PURCHASE COMMON STOCK Exhibit 4 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN COMPLIANCE WITH APPLICABLE STATE SECURITIES LAWS OR BLUE SKY LAWS.
June 26, 2023	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin
June 21, 2023	EX-10.63	CONVERTIBLE PROMISSORY NOTE Exhibit 10.63 THIS CONVERTIBLE PROMISSORY NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR
June 21, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2023 REGENERX BIOPHARMAC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2023 REGENERX BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-15070 52-1253406 (State or other jurisdiction of incorporation) (Co
June 21, 2023	EX-10.64	REGENERX BIOPHARMACEUTICALS, INC. WARRANT TO PURCHASE COMMON STOCK Exhibit 10.64 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIV
May 15, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☑ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2023 ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to .
April 11, 2023	EX-99.1	Letter to stockholders dated April 11, 2023 Exhibit 99.1 15245 Shady Grove Road Suite 470 Rockville, MD 20850 301.208.9191 April 11, 2023 Dear Stockholder: Although there has been significant progress with our ophthalmic clinical program through our U.S. joint venture, ReGenTree LLC, progress has been slower than expected. According to our partner managing the JV, the phase 3 neurotrophic keratitis (NK) trials are expected to start enrollin
April 11, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ⌧ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15
April 3, 2023	NT 10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): x Form 10K ¨ Form 20F ¨ Form 11K ¨ Form 10Q ¨ Form 10D ¨ Form NSAR ¨ Form NCSR For Period Ended: December 31, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): x Form 10K ¨ Form 20F ¨ Form 11K ¨ Form 10Q ¨ Form 10D ¨ Form NSAR ¨ Form NCSR For Period Ended: December 31, 2022 ¨ Transition Report on Form 10K ¨ Transition Report on Form 20F ¨ Transition Report on Form 11K ¨ Transition Report on Form 10Q ¨ Transition Report on Form NSAR
November 14, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☑ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2022 ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to .
August 12, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ? ? Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2022 ? ? ? Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to .
May 16, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ? ? Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2022 ? ? ? Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to .
March 30, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 17, 2021	424B3	OFFERING PROSPECTUS 24,750,000 Shares of Common Stock Issued and Issuable upon the Exercise of Warrants Prospectus Supplement No. 1 (to Prospectus dated September 1, 2021) Filed Pursuant to Rule 424(b)(3) Registration No. 333-258873 OFFERING PROSPECTUS 24,750,000 Shares of Common Stock Issued and Issuable upon the Exercise of Warrants This prospectus supplement updates and supplements the prospectus dated September 1, 2021 (the ?Prospectus?), which forms a part of our Registration Statement on Form
November 15, 2021	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 REGENERX BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-15070 52-1253406 (State or other jurisdiction of incorporation)
November 15, 2021	EX-3.1	Exhibit 3.1 to Current Report on Form 8-K (File No. 001-15070) (filed November 15, 2021) Exhibit 3.1
November 15, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ? ? ? Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2021 ? ? ? ? Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to .
November 15, 2021	EX-99.1	2021 Annual Stockholders Meeting Exhibit 99.1 2021 Annual Stockholders Meeting 2 OTCQB: RGRX Forward - Looking Statements This presentation contains certain forward - looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward - looking statements . Examples of such forward - looking state
October 19, 2021	DEFR14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rul
October 18, 2021	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? ?
October 8, 2021	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State
September 3, 2021	CORRESP	September 3, 2021 September 3, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
September 2, 2021	S-1/A	As filed with the Securities and Exchange Commission on September 1, 2021 Table of Contents ? As filed with the Securities and Exchange Commission on September 1, 2021 Registration No.
August 16, 2021	S-1	As filed with the Securities and Exchange Commission on August 16, 2021 Table of Contents ? As filed with the Securities and Exchange Commission on August 16, 2021 Registration No.
August 6, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ? ? ? Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2021 ? ? ? ? Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to .
August 6, 2021	EX-10.3	Exhibit 10.3 to Quarterly Report on Form 10-Q (file No. 001-15070) filed August 6, 2021) Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST
August 6, 2021	EX-10.4	Exhibit 10.4 to Quarterly Report on Form 10-Q (file No. 001-15070) filed August 6, 2021) Exhibit 10.4 ? NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGI
August 6, 2021	EX-10.2	Exhibit 10.2 to Quarterly Report on Form 10-Q (file No. 001-15070) filed August 6, 2021) Exhibit 10.2 ? REGISTRATION RIGHTS AGREEMENT ? This Registration Rights Agreement (this ?Agreement?) is made and entered into as of June 28, 2021, between RegeneRx Biopharmaceuticals, Inc., a Delaware corporation (the ?Company?), and each of the several purchasers signatory hereto (each such purchaser, a ?Purchaser? and, collectively, the ?Purchasers?). ? This Agreement is made pursuant to the Sec
August 6, 2021	EX-10.1	Exhibit 10.1 to Quarterly Report on Form 10-Q (file No. 001-15070) filed August 6, 2021) Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of June 28, 2021, between RegeneRx Biopharmaceuticals, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subject to the terms and
August 6, 2021	EX-10.5	Exhibit 10.5 to Quarterly Report on Form 10-Q (file No. 001-15070) filed August 6, 2021) Exhibit 10.5 ? LOCK-UP AGREEMENT ? , 2021 ? Re: Securities Purchase Agreement, dated as of , 2021 (the ?Purchase Agreement?), between RegeneRx Biopharmaceuticals, Inc. (the ?Company?) and the purchasers signatory thereto (each, a ?Purchaser? and, collectively, the ?Purchasers?) Ladies and Gentlemen: Defined terms not otherwise defined in this letter agreement (the ?Letter Agreement?) shall have th
July 22, 2021	EX-99.1	1 Exhibit 99.1 RegeneRx Biopharmaceuticals Inc. PHONE 301.208.9191 15245 Shady Grove Road, Suite 470 FAX 301.208.9194 Rockville, Maryland 20850 WEB www.regenerx.com July 22, 2021 Dear Stockholder: The past few months have been very rewarding with respect to analysis of our ARISE-3 dry eye (DES) clinical trial, the data pooled from all three ARISE DES trials, and the receipt of $2 million of new capi
July 22, 2021	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2021 REGENERX BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-15070 52-1253406 (State or other jurisdiction of incorporation) (Co
July 2, 2021	EX-1	Joint Filing Agreement. EX-1 2 ea143641ex-1essetifin.htm JOINT FILING AGREEMENT. EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Schedule 13D with respect to the Common Stock of RegeneRx Biopharmaceuticals, Inc. dated as of July 2, 2021, is, and any amendments thereto signed by such of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule
July 2, 2021	SC 13D/A	RGRX / RegeneRx Biopharmaceuticals Inc / Essetifin SPA - AMENDMENT NO. 25 TO SCHEDULE 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A25 (Amendment No. 25) Under the Securities Exchange Act of 1934 RegeneRx Biopharmaceuticals, Inc. (Name of Issuer) Common Stock, Par Value $0.001 per share (Title of Class of Securities) 75886X 10 8 (CUSIP Number) Marino Zigrossi Managing Director Essetifin S.p.A. Via Sudafrica, 20 Rome, RM 00144 Italy +39 06 5427711 (Name, Ad
July 2, 2021	EX-2	Securities Purchase Agreement, dated as of June 28, 2021, by and between the Issuer and Aptafin S.p.A. eXHIBIT 2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of June 28, 2021, between RegeneRx Biopharmaceuticals, Inc.
July 2, 2021	EX-3	Form of 2021 Warrant. EXHIBIT 3 FORM OF 2021 WARRANTS NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.
July 1, 2021	EX-99.1	RegeneRx Biopharmaceuticals, Inc. Closes $2 Million Private Placement Exhibit 99.1 RegeneRx Biopharmaceuticals Inc. 15245 Shady Grove Road, Suite 470 PHONE 301.208.9191 FAX 301.208.9194 WEB www.regenerx.com RegeneRx Biopharmaceuticals, Inc. Closes $2 Million Private Placement ROCKVILLE, Md. (July 1, 2021) ? RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (?RegeneRx?), a clinical-stage drug development company focused on tissue protection, repair and regeneration), t
July 1, 2021	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2021 REGENERX BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-15070 52-1253406 (State or other jurisdiction of incorporation) (Co
May 14, 2021	EX-99.1	RegeneRx Joint Venture Reports Positive Results from ARISE-3 Clinical Trial Using RGN-259 to Treat Dry Eye Syndrome Pooled Data from Three Phase 3 Clinical Trials in ~1500 Patients Shows Statistically Significant Improvements of Signs and Symptoms of Exhibit 99.1 RegeneRx Biopharmaceuticals Inc. 15245 Shady Grove Road, Suite 470 Rockville, Maryland 20850 PHONE 301.208.9191 FAX 301.208.9194 WEB www.regenerx.com RegeneRx Joint Venture Reports Positive Results from ARISE-3 Clinical Trial Using RGN-259 to Treat Dry Eye Syndrome Pooled Data from Three Phase 3 Clinical Trials in ~1500 Patients Shows Statistically Significant Improvements of Signs an
May 14, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2021 REGENERX BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-15070 52-1253406 (State or other jurisdiction of incorporation) (Com
May 14, 2021	10-Q	United States Securities and Exchange Commission Washington, DC 20549 FORM 10-Q 10-Q 1 tm2111763d110q.htm FORM 10-Q United States Securities and Exchange Commission Washington, DC 20549 FORM 10-Q þ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2021 ¨ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission file numbe
March 19, 2021	EX-99.1	1 Exhibit 99.1 RegeneRx Biopharmaceuticals Inc. 15245 Shady Grove Road, Suite 470 Rockville, Maryland 20850 PHONE 301.208.9191 FAX 301.208.9194 WEB www.regenerx.com RegeneRx Reports Topline Results of ARISE-3 Dry Eye Trial ROCKVILLE, Md. (March 18, 2021) – RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (the “Company” or “RegeneRx”), a clinical-stage biopharmaceutical company focused on tissue prote
March 19, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2021 REGENERX BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-15070 52-1253406 (State or other jurisdiction of incorporation) (C
March 2, 2021	10-K	Annual Report - FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15070 RegeneRx Bioph
November 13, 2020	EX-10.1	Exhibit 10.1 to Quarterly Report on Form 10-Q (File No. 001-15070) (filed November 13, 2020) Exhibit 10.1 REGENERX BIOPHARMACEUTICALS, INC. CONVERTIBLE NOTE AND WARRANT PURCHASE AGREEMENT October 15, 2020 Table of Contents Page SECTION 1. DEFINITIONS 1 SECTION 2. ISSUANCE AND SALE OF THE SECURITIES 3 2.1 Funding 3 SECTION 3. THE FUNDING 3 3.1 Funding 3 3.2 Deliveries by the Company 4 3.3 Deliveries by the Investor 4 SECTION 4. REPRESENTATIONS, WARRANTIES AND COVENANTS 4 4.1 Representation
November 13, 2020	10-Q	Quarterly Report - FORM 10-Q United States Securities and Exchange Commission Washington, DC 20549 FORM 10-Q x Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2020 ¨ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to .
November 13, 2020	EX-10.2	Exhibit 10.3 to Quarterly Report on Form 10-Q (File No. 001-15070) (filed November 13, 2020) Exhibit 10.2 THIS CONVERTIBLE PROMISSORY NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR A
November 13, 2020	EX-10.3	Exhibit 10.3 to Quarterly Report on Form 10-Q (File No. 001-15070) (filed November 13, 2020) Exhibit 10.3 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
October 21, 2020	EX-99.1	RegeneRx Closes Convertible Debt Financing Exhibit 99.1 RegeneRx Biopharmaceuticals Inc. 15245 Shady Grove Road, Suite 470 Rockville, Maryland 20850 PHONE 301.208.9191 FAX 301.208.9194 WEB www.regenerx.com News Release RegeneRx Closes Convertible Debt Financing ROCKVILLE, Md. (October 21, 2020) – RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“the Company” or “RegeneRx”), a clinical-stage drug development company focused on tissue protec
October 21, 2020	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2020 REGENERX BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-15070 52-1253406 (State or other jurisdiction of incorporation)
October 16, 2020	EX-99.6	Convertible Note and Warrant Purchase Agreement, dated October 15, 2020, between the Issuer and Essetifin. EXHIBIT 6 REGENERX BIOPHARMACEUTICALS, INC. CONVERTIBLE NOTE AND WARRANT PURCHASE AGREEMENT October 15, 2020 Table of Contents Page SECTION 1. DEFINITIONS 1 SECTION 2. ISSUANCE AND SALE OF THE SECURITIES 3 2.1 Funding 3 SECTION 3. THE FUNDING 3 3.1 Funding 3 3.2 Deliveries by the Company 4 3.3 Deliveries by the Investor 4 SECTION 4. REPRESENTATIONS, WARRANTIES AND COVENANTS 4 4.1 Representations a
October 16, 2020	EX-99.7	Form of October 2020 Note. EXHIBIT 7 THIS CONVERTIBLE PROMISSORY NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF.
October 16, 2020	SC 13D/A	RGRX / RegeneRx Biopharmaceuticals, Inc. / Essetifin SPA - AMENDMENT NO. 24 TO SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A24 (Amendment No. 24) Under the Securities Exchange Act of 1934 RegeneRx Biopharmaceuticals, Inc. (Name of Issuer) Common Stock, Par Value $0.001 per share (Title of Class of Securities) 75886X 10 8 (CUSIP Number) Marino Zigrossi Managing Director Essetifin S.p.A. Via Sudafrica, 20 Rome, RM 00144 Italy +39 06 542
October 16, 2020	EX-99.8	Form of October 2020 Warrant. EXHIBIT 8 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN COMPLIANCE WITH APPLICABLE STATE SECURITIES LAWS OR BLUE SKY LAWS.
October 13, 2020	8-K	Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2020 REGENERX BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-15070 52-1253406 (State or other jurisdiction of incorporation)
October 13, 2020	EX-99.1	RegeneRx Expects to Complete Short-Term Financing While Awaiting Completion of Phase 3 Clinical Trial for Dry Eye Syndrome Exhibit 99.1 RegeneRx Biopharmaceuticals Inc. 15245 Shady Grove Road, Suite 470 Rockville, Maryland 20850 PHONE 301.208.9191 FAX 301.208.9194 WEB www.regenerx.com RegeneRx Expects to Complete Short-Term Financing While Awaiting Completion of Phase 3 Clinical Trial for Dry Eye Syndrome ROCKVILLE, Md. (October 12, 2020) – RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“RegeneRx”), a clinical-stage
August 18, 2020	424B3	OFFERING PROSPECTUS 3,963,241 Shares Issuable upon the Exercise of Warrants Prospectus Supplement No. 8 (to Prospectus dated October 22, 2018) Filed Pursuant to Rule 424(b)(3) Registration No. 333-227786 OFFERING PROSPECTUS 3,963,241 Shares Issuable upon the Exercise of Warrants This prospectus supplement updates and supplements the prospectus dated October 22, 2018 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-2277
August 18, 2020	424B3	OFFERING PROSPECTUS 10,551,471 Shares of Common Stock 5,404,412 Shares Issuable upon the Exercise of Warrants Prospectus Supplement No. 19 (to Prospectus dated August 3, 2016) Filed Pursuant to Rule 424(b)(3) Registration No. 333-212606 OFFERING PROSPECTUS 10,551,471 Shares of Common Stock 5,404,412 Shares Issuable upon the Exercise of Warrants This prospectus supplement updates and supplements the prospectus dated August 3, 2016 (the “Prospectus”), which forms a part of our Registration Statement on Form
August 14, 2020	10-Q	Quarterly Report - FORM 10-Q United States Securities and Exchange Commission Washington, DC 20549 FORM 10-Q x Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2020 ¨ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to .
May 15, 2020	10-Q	Quarterly Report - FORM 10-Q United States Securities and Exchange Commission Washington, DC 20549 FORM 10-Q þ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2020 ¨ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to .
March 30, 2020	424B3	OFFERING PROSPECTUS 3,963,241 Shares Issuable upon the Exercise of Warrants Prospectus Supplement No. 7 (to Prospectus dated October 22, 2018) Filed Pursuant to Rule 424(b)(3) Registration No. 333-227786 OFFERING PROSPECTUS 3,963,241 Shares Issuable upon the Exercise of Warrants This prospectus supplement updates and supplements the prospectus dated October 22, 2018 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-2277
March 30, 2020	424B3	OFFERING PROSPECTUS 10,551,471 Shares of Common Stock 5,404,412 Shares Issuable upon the Exercise of Warrants Prospectus Supplement No. 18 (to Prospectus dated August 3, 2016) Filed Pursuant to Rule 424(b)(3) Registration No. 333-212606 OFFERING PROSPECTUS 10,551,471 Shares of Common Stock 5,404,412 Shares Issuable upon the Exercise of Warrants This prospectus supplement updates and supplements the prospectus dated August 3, 2016 (the “Prospectus”), which forms a part of our Registration Statement on Form
March 20, 2020	10-K	RGRX / RegeneRx Biopharmaceuticals, Inc. 10-K - Annual Report - FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15070 RegeneRx Bioph
November 19, 2019	424B3	OFFERING PROSPECTUS 10,551,471 Shares of Common Stock 5,404,412 Shares Issuable upon the Exercise of Warrants Prospectus Supplement No. 17 (to Prospectus dated August 3, 2016) Filed Pursuant to Rule 424(b)(3) Registration No. 333-212606 OFFERING PROSPECTUS 10,551,471 Shares of Common Stock 5,404,412 Shares Issuable upon the Exercise of Warrants This prospectus supplement updates and supplements the prospectus dated August 3, 2016 (the “Prospectus”), which forms a part of our Registration Statement on Form
November 19, 2019	424B3	OFFERING PROSPECTUS 3,963,241 Shares Issuable upon the Exercise of Warrants Prospectus Supplement No. 6 (to Prospectus dated October 22, 2018) Filed Pursuant to Rule 424(b)(3) Registration No. 333-227786 OFFERING PROSPECTUS 3,963,241 Shares Issuable upon the Exercise of Warrants This prospectus supplement updates and supplements the prospectus dated October 22, 2018 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-2277
November 14, 2019	EX-10.1	Amendment N. 1 to License Agreement dated February 25, 2019 between the Company and Lee’s Pharmaceutical (HK) Limited Exhibit 10.1 AMENDMENT N. 1 TO LICENSE AGREEMENT This amendment agreement (hereinafter “Amendment n. 1”), dated February 25, 2019 (hereinafter the “Amendment Date”), is entered into by and between RegeneRx Biopharmaceuticals, Inc., a company organized and existing under the laws of the state of Delaware, wit h offices at 15245 Shady Grove Road, Suite 470, Rockville, MD 20850, U.S.A. (hereinafter “
November 14, 2019	10-Q	RGRX / RegeneRx Biopharmaceuticals, Inc. 10-Q - Quarterly Report - FORM 10-Q United States Securities and Exchange Commission Washington, DC 20549 FORM 10-Q þ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2019 ¨ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to .
November 14, 2019	EX-10.2	Amendment No. 1 to RGN-259 License (PAN ASIA) dated September 17, 2019 between Company and GtreeBNT Co., Ltd. Exhibit 10.2 AMENDMENT NO. 1 TO RGN-259 LICENSE AGREEMENT (PAN ASIA) This Amendment No. 1 to License Agreement (this “Amendment”), dated September 17, 2019, amends that certain License Agreement (the “Agreement” or the “License Agreement”), dated effective March 7, 2014, by and between RegeneRx Biopharmaceuticals, Inc., (hereinafter “Licensor”), and GtreeBNT Co., Ltd. (formerly Digital Aria Co., L
September 30, 2019	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2019 REGENERX BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-15070 52-1253406 (State or other jurisdiction of incorporation
September 10, 2019	DEFA14A	RGRX / RegeneRx Biopharmaceuticals, Inc. DEFA14A - - DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin
August 30, 2019	DEF 14A	RGRX / RegeneRx Biopharmaceuticals, Inc. DEF 14A - - DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) þ Definitive Proxy State
August 21, 2019	PRE 14A	RGRX / RegeneRx Biopharmaceuticals, Inc. PRE 14A - - PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: þ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State
August 15, 2019	424B3	OFFERING PROSPECTUS 3,963,241 Shares Issuable upon the Exercise of Warrants Prospectus Supplement No. 5 (to Prospectus dated October 22, 2018) Filed Pursuant to Rule 424(b)(3) Registration No. 333-227786 OFFERING PROSPECTUS 3,963,241 Shares Issuable upon the Exercise of Warrants This prospectus supplement updates and supplements the prospectus dated October 22, 2018 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-2277
August 15, 2019	424B3	OFFERING PROSPECTUS 10,551,471 Shares of Common Stock 5,404,412 Shares Issuable upon the Exercise of Warrants Prospectus Supplement No. 16 (to Prospectus dated August 3, 2016) Filed Pursuant to Rule 424(b)(3) Registration No. 333-212606 OFFERING PROSPECTUS 10,551,471 Shares of Common Stock 5,404,412 Shares Issuable upon the Exercise of Warrants This prospectus supplement updates and supplements the prospectus dated August 3, 2016 (the “Prospectus”), which forms a part of our Registration Statement on Form
August 14, 2019	10-Q	RGRX / RegeneRx Biopharmaceuticals, Inc. 10-Q - Quarterly Report - FORM 10-Q United States Securities and Exchange Commission Washington, DC 20549 FORM 10-Q þ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2019 ¨ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to .
May 16, 2019	424B3	OFFERING PROSPECTUS 3,963,241 Shares Issuable upon the Exercise of Warrants Prospectus Supplement No. 4 (to Prospectus dated October 22, 2018) Filed Pursuant to Rule 424(b)(3) Registration No. 333-227786 OFFERING PROSPECTUS 3,963,241 Shares Issuable upon the Exercise of Warrants This prospectus supplement updates and supplements the prospectus dated October 22, 2018 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-2277
May 16, 2019	424B3	OFFERING PROSPECTUS 10,551,471 Shares of Common Stock 5,404,412 Shares Issuable upon the Exercise of Warrants Prospectus Supplement No. 15 (to Prospectus dated August 3, 2016) Filed Pursuant to Rule 424(b)(3) Registration No. 333-212606 OFFERING PROSPECTUS 10,551,471 Shares of Common Stock 5,404,412 Shares Issuable upon the Exercise of Warrants This prospectus supplement updates and supplements the prospectus dated August 3, 2016 (the “Prospectus”), which forms a part of our Registration Statement on Form
May 16, 2019	SC 13D/A	RGRX / RegeneRx Biopharmaceuticals, Inc. / Essetifin Spa - AMENDMENT NO. 23 TO SCHEDULE 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A23 (Amendment No. 23) Under the Securities Exchange Act of 1934 RegeneRx Biopharmaceuticals, Inc. (Name of Issuer) Common Stock, Par Value $0.001 per share (Title of Class of Securities) 75886X 10 8 (CUSIP Number) Marino Zigrossi Managing Director Essetifin S.p.A. Via Sudafrica, 20 Rome, RM 00144 Italy +39 06 5427711 (Name, Ad
May 15, 2019	EX-10.2	Exhibit 10.2 to Quarterly Report on Form 10-Q (File No. 001-15070) (filed May 15, 2019) Exhibit 10.2 THIS CONVERTIBLE PROMISSORY NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR A
May 15, 2019	10-Q	RGRX / RegeneRx Biopharmaceuticals, Inc. 10-Q Quarterly Report FORM 10-Q United States Securities and Exchange Commission Washington, DC 20549 FORM 10-Q þ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2019 ¨ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to .
May 15, 2019	EX-10.3	Exhibit 10.3 to Quarterly Report on Form 10-Q (File No. 001-15070) (filed May 15, 2019) Exhibit 10.3 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
May 15, 2019	EX-10.1	Exhibit 10.1 to Quarterly Report on Form 10-Q (File No. 001-15070) (filed May 15, 2019) Exhibit 10.1 REGENERX BIOPHARMACEUTICALS, INC. CONVERTIBLE NOTE AND WARRANT PURCHASE AGREEMENT February [], 2019 Table of Contents Page SECTION 1. DEFINITIONS 1 SECTION 2. ISSUANCE AND SALE OF THE SECURITIES 4 2.1 1st Funding 4 2.2 2nd Funding 4 SECTION 3. THE FUNDING 4 3.1 Funding 4 3.2 Deliveries by the Company 5 3.3 Deliveries by the Investor 5 SECTION 4. REPRESENTATIONS, WARRANTIES AND COVENAN
April 2, 2019	424B3	OFFERING PROSPECTUS 10,551,471 Shares of Common Stock 5,404,412 Shares Issuable upon the Exercise of Warrants Prospectus Supplement No. 14 (to Prospectus dated August 3, 2016) Filed Pursuant to Rule 424(b)(3) Registration No. 333-212606 OFFERING PROSPECTUS 10,551,471 Shares of Common Stock 5,404,412 Shares Issuable upon the Exercise of Warrants This prospectus supplement updates and supplements the prospectus dated August 3, 2016 (the “Prospectus”), which forms a part of our Registration Statement on Form
April 2, 2019	424B3	OFFERING PROSPECTUS 3,963,241 Shares Issuable upon the Exercise of Warrants Prospectus Supplement No. 3 (to Prospectus dated October 22, 2018) Filed Pursuant to Rule 424(b)(3) Registration No. 333-227786 OFFERING PROSPECTUS 3,963,241 Shares Issuable upon the Exercise of Warrants This prospectus supplement updates and supplements the prospectus dated October 22, 2018 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-2277
March 29, 2019	10-K	RGRX / RegeneRx Biopharmaceuticals, Inc. FORM 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15070 RegeneRx Bioph
March 29, 2019	EX-10.49	Exhibit 10.49 to Annual Report on Form 10-K (File No. 001-15070) (filed March 29, 2019) Exhibit 10.49 RegeneRx Biopharmaceuticals, Inc. 2018 Equity Incentive Plan Adopted by the Board of Directors Effective as of & Approved by the Stockholders: June 13, 2018 Termination Date: June 13, 2028 1. General. (a) Eligible Award Recipients. The persons eligible to receive Awards are Employees, Directors and Consultants. (b) Available Awards. The Plan provides for the grant of the following Aw
March 5, 2019	424B3	OFFERING PROSPECTUS 10,551,471 Shares of Common Stock 5,404,412 Shares Issuable upon the Exercise of Warrants Prospectus Supplement No. 12 (to Prospectus dated August 3, 2016) Filed Pursuant to Rule 424(b)(3) Registration No. 333-212606 OFFERING PROSPECTUS 10,551,471 Shares of Common Stock 5,404,412 Shares Issuable upon the Exercise of Warrants This prospectus supplement updates and supplements the prospectus dated August 3, 2016 (the “Prospectus”), which forms a part of our Registration Statement on Form
March 5, 2019	424B3	OFFERING PROSPECTUS 3,963,241 Shares Issuable upon the Exercise of Warrants Prospectus Supplement No. 2 (to Prospectus dated October 22, 2018) Filed Pursuant to Rule 424(b)(3) Registration No. 333-227786 OFFERING PROSPECTUS 3,963,241 Shares Issuable upon the Exercise of Warrants This prospectus supplement updates and supplements the prospectus dated October 22, 2018 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-2277
March 5, 2019	EX-99.1	RegeneRx Closes $1.3 Million Convertible Debt Financing Funding for Operations Over Next 12 Months During Phase 3 Ophthalmic Trials Exhibit 99.1 RegeneRx Biopharmaceuticals, Inc. 15245 Shady Grove Road, Suite 470 Rockville, Maryland 20850 PHONE 301.208.9191 FAX 301.208.9194 WEB www.regenerx.com News Release RegeneRx Closes $1.3 Million Convertible Debt Financing Funding for Operations Over Next 12 Months During Phase 3 Ophthalmic Trials ROCKVILLE, Md. (February 27, 2019) – RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“the
March 5, 2019	8-K	Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2019 REGENERX BIOPHARMACEUTICALS, INC.
March 1, 2019	EX-99.1	JOINT FILERS’ SIGNATURES Exhibit 99.1 JOINT FILERS’ SIGNATURES ESSETIFIN S.P.A. By: /s/ Marino Zigrossi Name: Marino Zigrossi Title: Managing Director Date: March 1, 2019 Enrico Cavazza By: /s/ Marino Zigrossi Name: Marino Zigrossi Title: Attorney-in-fact Date: March 1, 2019 Francesca Cavazza By: /s/ Marino Zigrossi Name: Marino Zigrossi Title: Attorney-in-fact Date: March 1, 2019 Silvia Cavazza By: /s/ Marino Zigross
March 1, 2019	SC 13D/A	Convertible Note and Warrant Purchase Agreement, dated February 26, 2019, between the Issuer and Essetifin.3 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A22 (Amendment No. 22) Under the Securities Exchange Act of 1934 RegeneRx Biopharmaceuticals, Inc. (Name of Issuer) Common Stock, Par Value $0.001 per share (Title of Class of Securities) 75886X 10 8 (CUSIP Number) Marino Zigrossi Managing Director Essetifin S.p.A. Via Sudafrica, 20 Rome, RM 00144 Italy +39 06 5427711 (Name, Ad
February 27, 2019	SC 13D/A	RGRX / RegeneRx Biopharmaceuticals, Inc. / Essetifin Spa - AMENDMENT NO. 22 TO SCHEDULE 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A22 (Amendment No. 22) Under the Securities Exchange Act of 1934 RegeneRx Biopharmaceuticals, Inc. (Name of Issuer) Common Stock, Par Value $0.001 per share (Title of Class of Securities) 75886X 10 8 (CUSIP Number) Marino Zigrossi Managing Director Essetifin S.p.A. Via Sudafrica, 20 Rome, RM 00144 Italy +39 06 5427711 (Name, Ad
November 15, 2018	424B3	OFFERING PROSPECTUS 3,963,241 Shares Issuable upon the Exercise of Warrants Prospectus Supplement No. 1 (to Prospectus dated October 22, 2018) Filed Pursuant to Rule 424(b)(3) Registration No. 333-227786 OFFERING PROSPECTUS 3,963,241 Shares Issuable upon the Exercise of Warrants This prospectus supplement updates and supplements the prospectus dated October 22, 2018 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-2277
November 15, 2018	424B3	OFFERING PROSPECTUS 10,551,471 Shares of Common Stock 5,404,412 Shares Issuable upon the Exercise of Warrants Prospectus Supplement No. 12 (to Prospectus dated August 3, 2016) Filed Pursuant to Rule 424(b)(3) Registration No. 333-212606 OFFERING PROSPECTUS 10,551,471 Shares of Common Stock 5,404,412 Shares Issuable upon the Exercise of Warrants This prospectus supplement updates and supplements the prospectus dated August 3, 2016 (the “Prospectus”), which forms a part of our Registration Statement on Form
November 14, 2018	10-Q	RGRX / RegeneRx Biopharmaceuticals, Inc. FORM 10-Q (Quarterly Report) United States Securities and Exchange Commission Washington, DC 20549 FORM 10-Q þ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2018 ¨ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to .
October 22, 2018	S-1/A	RGRX / RegeneRx Biopharmaceuticals, Inc. S-1/A As filed with the Securities and Exchange Commission on October 22, 2018 Registration No.
October 22, 2018	S-1/A	RGRX / RegeneRx Biopharmaceuticals, Inc. S-1/A As filed with the Securities and Exchange Commission on October 22, 2018 Registration No.
October 22, 2018	CORRESP	RGRX / RegeneRx Biopharmaceuticals, Inc. CORRESP October 22, 2018 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
October 11, 2018	S-1	RGRX / RegeneRx Biopharmaceuticals, Inc. S-1 As filed with the Securities and Exchange Commission on October 11, 2018 Registration No.
September 28, 2018	SC 13D/A	RGRX / RegeneRx Biopharmaceuticals, Inc. / Essetifin Spa - AMENDMENT NO. 21 TO SCHEDULE 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A21 (Amendment No. 21) Under the Securities Exchange Act of 1934 RegeneRx Biopharmaceuticals, Inc. (Name of Issuer) Common Stock, Par Value $0.001 per share (Title of Class of Securities) 75886X 10 8 (CUSIP Number) Marino Zigrossi Managing Director Essetifin S.p.A. Via Sudafrica, 20 Rome, RM 00144 Italy +39 06 5427711 (Name, Ad
August 14, 2018	424B3	OFFERING PROSPECTUS 10,551,471 Shares of Common Stock 5,404,412 Shares Issuable upon the Exercise of Warrants Prospectus Supplement No. 11 (to Prospectus dated August 3, 2016) Filed Pursuant to Rule 424(b)(3) Registration No. 333-212606 OFFERING PROSPECTUS 10,551,471 Shares of Common Stock 5,404,412 Shares Issuable upon the Exercise of Warrants This prospectus supplement updates and supplements the prospectus dated August 3, 2016 (the “Prospectus”), which forms a part of our Registration Statement on Form
August 13, 2018	424B3	OFFERING PROSPECTUS 10,551,471 Shares of Common Stock 5,404,412 Shares Issuable upon the Exercise of Warrants Prospectus Supplement No. 10 (to Prospectus dated August 3, 2016) Filed Pursuant to Rule 424(b)(3) Registration No. 333-212606 OFFERING PROSPECTUS 10,551,471 Shares of Common Stock 5,404,412 Shares Issuable upon the Exercise of Warrants This prospectus supplement updates and supplements the prospectus dated August 3, 2016 (the “Prospectus”), which forms a part of our Registration Statement on Form
August 9, 2018	10-Q	RGRX / RegeneRx Biopharmaceuticals, Inc. 10-Q (Quarterly Report) United States Securities and Exchange Commission Washington, DC 20549 FORM 10-Q þ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2018 ¨ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to .
June 15, 2018	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2018 REGENERX BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-15070 52-1253406 (State or other jurisdiction of incorporation) (Co
May 16, 2018	424B3	OFFERING PROSPECTUS 10,551,471 Shares of Common Stock 5,404,412 Shares Issuable upon the Exercise of Warrants Prospectus Supplement No. 9 (to Prospectus dated August 3, 2016) Filed Pursuant to Rule 424(b)(3) Registration No. 333-212606 OFFERING PROSPECTUS 10,551,471 Shares of Common Stock 5,404,412 Shares Issuable upon the Exercise of Warrants This prospectus supplement updates and supplements the prospectus dated August 3, 2016 (the “Prospectus”), which forms a part of our Registration Statement on Form
May 15, 2018	DEF 14A	RGRX / RegeneRx Biopharmaceuticals, Inc. DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) þ Definitive Proxy State
May 15, 2018	10-Q	United States Securities and Exchange Commission Washington, DC 20549 FORM 10-Q United States Securities and Exchange Commission Washington, DC 20549 FORM 10-Q ? Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2018 ? Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to .
April 25, 2018	EX-99.1	GtreeBNT Discloses Preliminary Observations from Seventeen NK Patients Treated with RGN-259 Eye Drops Exhibit 99.1 RegeneRx Biopharmaceuticals Inc. 15245 Shady Grove Road, Suite 470 Rockville, Maryland 20850 PHONE 301.208.9191 FAX 301.208.9194 WEB www.regenerx.com News Release GtreeBNT Discloses Preliminary Observations from Seventeen NK Patients Treated with RGN-259 Eye Drops Rockville, Md. (April 25, 2018) – RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“the Company” or “RegeneRx”), a clinica
April 25, 2018	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2018 REGENERX BIOPHARMACEUTICALS, INC.
April 2, 2018	424B3	OFFERING PROSPECTUS 10,551,471 Shares of Common Stock 5,404,412 Shares Issuable upon the Exercise of Warrants Prospectus Supplement No. 8 (to Prospectus dated August 3, 2016) Filed Pursuant to Rule 424(b)(3) Registration No. 333-212606 OFFERING PROSPECTUS 10,551,471 Shares of Common Stock 5,404,412 Shares Issuable upon the Exercise of Warrants This prospectus supplement updates and supplements the prospectus dated August 3, 2016 (the “Prospectus”), which forms a part of our Registration Statement on Form
March 29, 2018	EX-10.48	Exhibit 10.48 to Annual Report (File No. 001-15070) (filed March 29, 2018) Exhibit 10.48 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIS
March 29, 2018	EX-10.47	Warrant Reprice Agreement between the Company and the Purchasers identified therein dated March 2, 2018 Exhibit 10.47 REGENERX BIOPHARMACEUTICALS, INC. March 2, 2018 Sabby Healthcare Master Fund, Ltd. c/o Sabby Management, LLC 10 Mountainview Road, Suite 205 Upper Saddle River, NJ 07458 Sabby Volatility Warrant Master Fund, Ltd. c/o Sabby Management, LLC 10 Mountainview Road, Suite 205 Upper Saddle River, NJ 07458 Re: Reset Offer of Common Stock Purchase Warrants To Whom It May Concern: RegeneRx Bio
March 29, 2018	10-K	RGRX / RegeneRx Biopharmaceuticals, Inc. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15070 RegeneRx Bioph
March 14, 2018	SC 13D/A	RGRX / RegeneRx Biopharmaceuticals, Inc. / Essetifin Spa - AMENDMENT NO. 20 TO SCHEDULE 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A20 (Amendment No. 20) Under the Securities Exchange Act of 1934 RegeneRx Biopharmaceuticals, Inc. (Name of Issuer) Common Stock, Par Value $0.001 per share (Title of Class of Securities) 75886X 10 8 (CUSIP Number) Marino Zigrossi Managing Director Essetifin S.p.A. Via Sudafrica, 20 Rome, RM 00144 Italy +39 06 5427711 (Name, Ad
March 6, 2018	424B3	OFFERING PROSPECTUS 10,551,471 Shares of Common Stock 5,404,412 Shares Issuable upon the Exercise of Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-212606 Prospectus Supplement No. 7 (to Prospectus dated August 3, 2016) OFFERING PROSPECTUS 10,551,471 Shares of Common Stock 5,404,412 Shares Issuable upon the Exercise of Warrants This prospectus supplement updates and supplements the prospectus dated August 3, 2016 (the “Prospectus”), which forms a part of our Registration Statement on Form
March 2, 2018	EX-99.1	RegeneRx Secures $1 Million in Funding Exhibit 99.1 RegeneRx Secures $1 Million in Funding ROCKVILLE, Md. (March 2, 2018) – RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“the Company” or “RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that it entered into a Warrant Reprice Agreement whereby it received $1.03 million in warrant exercise proceeds. This is in
March 2, 2018	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2018 REGENERX BIOPHARMACEUTICALS, INC.
November 14, 2017	10-Q	RGRX / RegeneRx Biopharmaceuticals, Inc. 10-Q (Quarterly Report) United States Securities and Exchange Commission Washington, DC 20549 FORM 10-Q þ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2017 ¨ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to .
November 14, 2017	EX-10.1	Amendment No 2. Dated as of August 28, 2017, REN-137 License Agreement between the Company and GTreeBNT Co., LTD, dated March 7, 2014 Exhibit 10.1 Amendment NO. 2 to RGN-137 LICENSE Agreement (U.S.) This Amendment No. 2 to License Agreement (this “Amendment”), effective as of August 28, 2017 (the “Effective Date”), amends that certain License Agreement (the “Agreement” or the “License Agreement”), dated effective March 7, 2014, by and between RegeneRx Biopharmaceuticals, Inc., (hereinafter “Licensor”), and GtreeBNT Co., Ltd. (fo
November 14, 2017	424B3	OFFERING PROSPECTUS 10,551,471 Shares of Common Stock 5,404,412 Shares Issuable upon the Exercise of Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-212606 Prospectus Supplement No. 6 (to Prospectus dated August 3, 2016) OFFERING PROSPECTUS 10,551,471 Shares of Common Stock 5,404,412 Shares Issuable upon the Exercise of Warrants This prospectus supplement updates and supplements the prospectus dated August 3, 2016 (the ?Prospectus?), which forms a part of our Registration Statement on Form
October 17, 2017	SC 13D/A	Joint Filing Agreement.1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A19 (Amendment No. 19) Under the Securities Exchange Act of 1934 RegeneRx Biopharmaceuticals, Inc. (Name of Issuer) Common Stock, Par Value $0.001 per share (Title of Class of Securities) 75886X 10 8 (CUSIP Number) Marino Zigrossi Managing Director Essetifin S.p.A. Via Sudafrica, 20 Rome, RM 00144 Italy +39 06 5427711 (Name, Ad
September 15, 2017	424B3	OFFERING PROSPECTUS 10,551,471 Shares of Common Stock 5,404,412 Shares Issuable upon the Exercise of Warrants Prospectus Supplement No. 5 (to Prospectus dated August 3, 2016) Filed Pursuant to Rule 424(b)(3) Registration No. 333-212606 OFFERING PROSPECTUS 10,551,471 Shares of Common Stock 5,404,412 Shares Issuable upon the Exercise of Warrants This prospectus supplement updates and supplements the prospectus dated August 3, 2016 (the ?Prospectus?), which forms a part of our Registration Statement on Form
August 31, 2017	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2017 REGENERX BIOPHARMACEUTICALS, INC.
August 31, 2017	EX-99.1	RegeneRx Completes License Expansion for RGN-137 in Europe, S. Korea, Japan, Canada and Australia Proceeds will Fund Operations Beyond Receipt of Phase 3 Dry Eye Trial Data Exhibit 99.1 RegeneRx Biopharmaceuticals Inc. 15245 Shady Grove Road, Suite 470 Rockville, Maryland 20850 PHONE 301.208.9191 FAX 301.208.9194 WEB www.regenerx.com News Release RegeneRx Completes License Expansion for RGN-137 in Europe, S. Korea, Japan, Canada and Australia Proceeds will Fund Operations Beyond Receipt of Phase 3 Dry Eye Trial Data ROCKVILLE, Md. (August 31, 2017) ? RegeneRx Biophar
August 21, 2017	10-Q	RGRX / RegeneRx Biopharmaceuticals, Inc. FORM 10-Q (Quarterly Report) United States Securities and Exchange Commission Washington, DC 20549 FORM 10-Q þ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2017 ¨ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to .
August 14, 2017	NT 10-Q	RegeneRx Biopharmaceuticals NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ? Form 10-K ? Form 20-F ? Form 11-K x Form 10-Q ? Form N-SAR ? Form N-CSR For Period Ended: June 30, 2017 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
May 16, 2017	424B3	OFFERING PROSPECTUS 10,551,471 Shares of Common Stock 5,404,412 Shares Issuable upon the Exercise of Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-212606 Prospectus Supplement No. 4 (to Prospectus dated August 3, 2016) OFFERING PROSPECTUS 10,551,471 Shares of Common Stock 5,404,412 Shares Issuable upon the Exercise of Warrants This prospectus supplement updates and supplements the prospectus dated August 3, 2016 (the ?Prospectus?), which forms a part of our Registration Statement on Form
May 15, 2017	10-Q	United States Securities and Exchange Commission Washington, DC 20549 FORM 10-Q United States Securities and Exchange Commission Washington, DC 20549 FORM 10-Q þ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2017 ¨ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to .
April 17, 2017	424B3	OFFERING PROSPECTUS 10,551,471 Shares of Common Stock 5,404,412 Shares Issuable upon the Exercise of Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-212606 Prospectus Supplement No. 3 (to Prospectus dated August 3, 2016) OFFERING PROSPECTUS 10,551,471 Shares of Common Stock 5,404,412 Shares Issuable upon the Exercise of Warrants This prospectus supplement updates and supplements the prospectus dated August 3, 2016 (the “Prospectus”), which forms a part of our Registration Statement on Form
March 29, 2017	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15070 RegeneRx Bioph
March 13, 2017	8-K	RegeneRx Biopharmaceuticals 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2017 REGENERX BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-15070 52-1253406 (State or other jurisdiction of incorporation) (C
March 13, 2017	EX-99.1	March 13, 2017 Exhibit 99.1 15245 Shady Grove Road Suite 470 Rockville, MD 20850 301.208.9191 March 13, 2017 Dear Shareholder: We would like to take this time to report on the business activities and accomplishments of RegeneRx in 2016 and the clinical milestones that we expect to reach in 2017. This letter will provide an update on our various partnerships, clinical trials, and operations. We reserve the right
November 15, 2016	424B3	OFFERING PROSPECTUS 10,551,471 Shares of Common Stock 5,404,412 Shares Issuable upon the Exercise of Warrants Prospectus Supplement No. 2 (to Prospectus dated August 3, 2016) Filed Pursuant to Rule 424(b)(3) Registration No. 333-212606 OFFERING PROSPECTUS 10,551,471 Shares of Common Stock 5,404,412 Shares Issuable upon the Exercise of Warrants This prospectus supplement updates and supplements the prospectus dated August 3, 2016 (the ?Prospectus?), which forms a part of our Registration Statement on Form
November 14, 2016	10-Q	United States Securities and Exchange Commission Washington, DC 20549 FORM 10-Q United States Securities and Exchange Commission Washington, DC 20549 FORM 10-Q ? Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2016 ? Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to .
November 1, 2016	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2016 REGENERX BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-15070 52-1253406 (State or other jurisdiction of incorporation)
September 16, 2016	DEF 14A	RegeneRx Biopharmaceuticals DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State
September 12, 2016	EX-99.1	Rodman & Renshaw 18 th Annual Global Investment Conference September 2016 Exhibit 99.1 Rodman & Renshaw 18 th Annual Global Investment Conference September 2016 2 OTCQB: RGRX Forward - Looking Statements This investor presentation contains certain forward - looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward - looking sta
September 12, 2016	8-K	RegeneRx Biopharmaceuticals FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2016 REGENERX BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-15070 52-1253406 (State or other jurisdiction of incorporation
August 23, 2016	424B3	OFFERING PROSPECTUS 10,551,471 Shares of Common Stock 5,404,412 Shares Issuable upon the Exercise of Warrants Prospectus Supplement No. 1 (to Prospectus dated August 3, 2016) Filed Pursuant to Rule 424(b)(3) Registration No. 333-212606 OFFERING PROSPECTUS 10,551,471 Shares of Common Stock 5,404,412 Shares Issuable upon the Exercise of Warrants This prospectus supplement updates and supplements the prospectus dated August 3, 2016 (the ?Prospectus?), which forms a part of our Registration Statement on Form
August 22, 2016	10-Q	United States Securities and Exchange Commission Washington, DC 20549 FORM 10-Q United States Securities and Exchange Commission Washington, DC 20549 FORM 10-Q ? Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2016 ? Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to .
August 22, 2016	EX-10.2	Amendment No. 2. to Joint Venture Agreement between the Company and GtreeBNT Co., Ltd. dated May 11, 2016. EXHIBIT 10.2
August 22, 2016	EX-10.2	Amendment No. 2. to Joint Venture Agreement between the Company and GtreeBNT Co., Ltd. dated May 11, 2016. EXHIBIT 10.2
August 22, 2016	10-Q	United States Securities and Exchange Commission Washington, DC 20549 FORM 10-Q United States Securities and Exchange Commission Washington, DC 20549 FORM 10-Q ? Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2016 ? Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to .
August 22, 2016	EX-10.1	Amendment No. 2 to the RGN-259 License Agreement between the Company and ReGenTree, LLC dated April 28, 2016. EXHIBIT 10.1
August 22, 2016	EX-10.1	Amendment No. 2 to the RGN-259 License Agreement between the Company and ReGenTree, LLC dated April 28, 2016. EXHIBIT 10.1
August 15, 2016	NT 10-Q	RegeneRx Biopharmaceuticals NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ? Form 10-K ? Form 20-F ? Form 11-K x Form 10-Q ? Form N-SAR ? Form N-CSR For Period Ended: June 30, 2016 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
August 15, 2016	NT 10-Q	RegeneRx Biopharmaceuticals NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ? Form 10-K ? Form 20-F ? Form 11-K x Form 10-Q ? Form N-SAR ? Form N-CSR For Period Ended: June 30, 2016 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
August 4, 2016	424B3	OFFERING PROSPECTUS 10,551,471 Shares of Common Stock 5,404,412 Shares Issuable upon the Exercise of Warrants Filed Pursuant to Rule 424(b)(3) File No. 333-212606 OFFERING PROSPECTUS 10,551,471 Shares of Common Stock 5,404,412 Shares Issuable upon the Exercise of Warrants The selling stockholders identified beginning on page 27 of this prospectus are offering on a resale basis a total of 10,551,471 shares of our common stock, of which 5,404,412 are issuable upon the exercise of outstanding warrants. We wi
August 2, 2016	DEL AM	RegeneRx Biopharmaceuticals DEL AM August 2, 2016 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
August 2, 2016	CORRESP	RegeneRx Biopharmaceuticals ESP August 2, 2016 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
July 29, 2016	S-1/A	As filed with the Securities and Exchange Commission on July 29, 2016 As filed with the Securities and Exchange Commission on July 29, 2016 Registration No.
July 21, 2016	S-1	As filed with the Securities and Exchange Commission on July 20, 2016 As filed with the Securities and Exchange Commission on July 20, 2016 Registration No.
July 1, 2016	EX-10.2	Registration Rights Agreement between the Company and Purchasers identified therein dated June 27, 2016. Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of June 27, 2016, between RegeneRx Biopharmaceuticals, Inc., a Delaware corporation (the ?Company?), and each of the several purchasers signatory hereto (each such purchaser, a ?Purchaser? and, collectively, the ?Purchasers?). This Agreement is made pursuant to the Securitie
July 1, 2016	EX-99.1	RegeneRx Announces $1.75 Million Private Placement Exhibit 99.1 RegeneRx Announces $1.75 Million Private Placement ROCKVILLE, Md., June 27, 2016 /PRNewswire/ ? RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that it has entered into a definitive agreement to sell 5,147,059 shares of common stock at a purch
July 1, 2016	EX-4.1	Exhibit 4.1 to Current Report on Form 8-K (File No. 001-15070) (filed July 1, 2016) Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
July 1, 2016	EX-10.1	Securities Purchase Agreement between the Company and Purchasers identified therein dated June 27, 2016. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of June 27, 2016, between RegeneRx Biopharmaceuticals, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subject to the terms and
July 1, 2016	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2016 REGENERX BIOPHARMACEUTICALS, INC.
July 1, 2016	EX-4.2	Exhibit 4.2 to Current Report on Form 8-K (File No. 001-15070) (filed July 1, 2016) Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
May 16, 2016	10-Q	United States Securities and Exchange Commission Washington, DC 20549 FORM 10-Q United States Securities and Exchange Commission Washington, DC 20549 FORM 10-Q ? Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2016 ? Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to .
April 11, 2016	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15070 RegeneRx Bioph
April 11, 2016	EX-10.41	Exhibit 10.41 to Annual Report on Form 10-K (File No. 001-15070) (filed April 11, 2016) Exhibit 10.41
March 30, 2016	NT 10-K	RegeneRx Biopharmaceuticals NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): x Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form N-SAR ? Form N-CSR For Period Ended: December 31, 2015 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
November 13, 2015	10-Q	United States Securities and Exchange Commission Washington, DC 20549 FORM 10-Q United States Securities and Exchange Commission Washington, DC 20549 FORM 10-Q ? Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2015 ? Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to .
September 29, 2015	8-K	RegeneRx Biopharmaceuticals FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2015 REGENERX BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-15070 52-1253406 (State or other jurisdiction of incorporation
August 14, 2015	10-Q	United States Securities and Exchange Commission Washington, DC 20549 FORM 10-Q United States Securities and Exchange Commission Washington, DC 20549 FORM 10-Q ? Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2015 ? Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to .
August 10, 2015	DEF 14A	RegeneRx Biopharmaceuticals DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) þ Definitive Proxy State
May 15, 2015	EX-10.1	Joint Venture Agreement between the Company and GtreeBNT Co., Ltd. dated January 28, 2015 Exhibit 10.1 JOINT VENTURE AGREEMENT This Joint Venture Agreement (this ?Agreement?) dated and effective as of January 28, 2015 (the ?Effective Date?), is entered into by and among: 1. G-treeBNT Co., Ltd., a corporation organized under the laws of the Republic of Korea (?Korea?) with offices at 22nd FL, Parkview Tower, 248 Jungjail-ro, Bundang-gu, Seongnam-si, Gyeonggi-do 463-863, Republic of Kore
May 15, 2015	EX-10.2	Exhibit 10.2 to Quarterly Report on Form 10-Q (File No. 001-15070) (filed May 15, 2015) Exhibit 10.2 RGN-259 U.S. LICENSE Agreement This License Agreement (this ?Agreement? or this ?License Agreement?) is effective as of January 28, 2015 (the ?Effective Date?), by and among RegeneRx Biopharmaceuticals, Inc., a company organized and existing under the laws of the state of Delaware, with offices at 15245 Shady Grove Road, Suite 470, Rockville, Maryland, U.S.A. (hereinafter ?Licensor?),
May 15, 2015	10-Q	United States Securities and Exchange Commission Washington, DC 20549 FORM 10-Q United States Securities and Exchange Commission Washington, DC 20549 FORM 10-Q ? Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2015 ? Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to .
April 1, 2015	SC 13D/A	RGRX / RegeneRx Biopharmaceuticals, Inc. / G-treeBNT Co., Ltd. - G-TREEBNT CO., LTD. SCHEDULE 13D/A 4-1-15 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D/A (Amendment No.
March 31, 2015	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15070 RegeneRx Bioph
February 19, 2015	EX-99.1	February 17, 2015 Exhibit 99.1 15245 Shady Grove Road Suite 470 Rockville, MD 20850\| 301.208.9191 February 17, 2015 Dear Shareholder: Having just completed a very important licensing and joint venture agreement to more rapidly move our ophthalmic drug candidate forward in the U.S., we would like to take this time to report on the status of RegeneRx and the exciting prospects for both the short term and long term fu
February 19, 2015	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2015 REGENERX BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-15070 52-1253406 (State or other jurisdiction of incorporation)
February 11, 2015	EX-99.1	RegeneRx and G-treeBNT Create Joint Venture to Develop RGN-259 in the U.S. Exhibit 99.1 RegeneRx and G-treeBNT Create Joint Venture to Develop RGN-259 in the U.S. ROCKVILLE, Md. (January 28, 2015) – RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“the Company” or “RegeneRx”) today announced that it has entered into agreements with G-treeBNT Co. Ltd., to develop RGN-259 for dry eye syndrome and neurotrophic keratitis (an orphan indication) in the United States. Under the
February 11, 2015	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2015 REGENERX BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-15070 52-1253406 (State or other jurisdiction of incorporation)
December 29, 2014	EX-24	EX-24 POWER OF ATTORNEY The undersigned hereby constitutes and appoints J.J. Finkelstein, Dane Saglio, Todd A. Taylor or Andrew Nick, or either of them acting alone, the undersigned's true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for the undersigned and in the undersigned's name, place and stead, in any and all capacities, to sign any or all Forms 4 and F
December 29, 2014	SC 13D	RGRX / RegeneRx Biopharmaceuticals, Inc. / MCNAY JOSEPH C - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* RegeneRx Biopharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 75886X 10 8 (CUSIP Number) Joseph C. McNay c/o Essex Investments 125 High Street Boston, MA 02110 617-342-3298 (Name, Address and Telephone Number of Person Aut
November 10, 2014	10-Q	United States Securities and Exchange Commission Washington, DC 20549 FORM 10-Q þ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 United States Securities and Exchange Commission Washington, DC 20549 FORM 10-Q ? Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2014 ? Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to .
November 7, 2014	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2014 REGENERX BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-15070 52-1253406 (State or other jurisdiction of incorporation)
October 9, 2014	EX-10.1	Exhibit 10.1 to Current Report on Form 8-K (File No. 001-15070) (filed October 9, 2014) Exhibit 10.1 FIRST AMENDMENT TO CONVERTIBLE PROMISSORY NOTE This First Amendment to the Convertible Promissory Note (the “Amendment”) is entered into this 3rd day of October, 2014 (the “Effective Date”), by and between (the “Holder”) and RegeneRx Biopharmaceuticals, Inc., a Delaware corporation (the “Company”). WHEREAS, the Company and the Holder have entered into a Convertible Notes and Warrant P
October 9, 2014	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2014 REGENERX BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-15070 52-1253406 (State or other jurisdiction of incorporation) (
September 15, 2014	8-K	Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2014 REGENERX BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-15070 52-1253406 (State or other jurisdiction of incorporation
September 15, 2014	EX-99.1	Corporate Presentation Annual Shareholder’s Meeting September 2014 Exhibit 99.1 Corporate Presentation Annual Shareholder’s Meeting September 2014 2 Forward - Looking Statements This presentation contains certain forward - looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward - looking statements . Examples of such f
September 3, 2014	SC 13D/A	RGRX / RegeneRx Biopharmaceuticals, Inc. / G-treeBNT Co., Ltd. - G-TREEBNT CO., LTD. SCHEDULE 13D/A 9-3-14 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D/A (Amendment No.
September 3, 2014	EX-99.1	RegeneRx Receives $1 Million Pursuant to Product License and Stock Purchase Agreement Exhibit 99.1 RegeneRx Receives $1 Million Pursuant to Product License and Stock Purchase Agreement ROCKVILLE, Md. (September 3, 2014) ? RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) (?the Company? or ?RegeneRx?) today announced that it received a payment of $1 million, representing the last tranche of a $2.5 million product license and securities purchase agreement with G-treeBNT Co., Ltd, to deve
September 3, 2014	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2014 REGENERX BIOPHARM UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2014 REGENERX BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-15070 52-1253406 (State or other jurisdiction of incorporation) (
August 14, 2014	EX-10.3	Exhibit 10.3 to Quarterly Report on Form10-Q (File No. 001-15070) (filed August 14, 2014) Exhibit 10.3 Executive EMPLOYMENT AGREEMENT This Executive Employment Agreement (the ?Agreement?) is entered into as of April 16, 2014 (the ?Effective Date?) between RegeneRx Biopharmaceuticals, Inc., a Delaware corporation (the ?Company?), and Dane Saglio (the ?Executive?). Recitals Whereas, the parties previously entered into an amended Consulting Agreement effective January 1, 2014 and now desi
August 14, 2014	EX-10.1	Executive Employment Agreement between the Company and J.J. Finkelstein dated April 16, 2014 Exhibit 10.1 Executive EMPLOYMENT AGREEMENT This Executive Employment Agreement (the ?Agreement?) is entered into as of April 16, 2014 (the ?Effective Date?) between RegeneRx Biopharmaceuticals, Inc., a Delaware corporation (the ?Company?), and J.J. Finkelstein (the ?Executive?). Recitals Whereas, the parties previously entered into an Employment Agreement which was terminated in December 2011 and
August 14, 2014	10-Q	United States Securities and Exchange Commission Washington, DC 20549 FORM 10-Q United States Securities and Exchange Commission Washington, DC 20549 FORM 10-Q ? Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2014 ? Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to .
August 14, 2014	EX-10.2	Executive Employment Agreement between the Company and Allan L. Goldstein dated April 16, 2014 Exhibit 10.2 Executive EMPLOYMENT AGREEMENT This Executive Employment Agreement (the ?Agreement?) is entered into as of April 16, 2014 (the ?Effective Date?) between RegeneRx Biopharmaceuticals, Inc., a Delaware corporation (the ?Company?), and Allan L. Goldstein (the ?Executive?). Recitals Whereas, the parties previously entered into an Employment Agreement which was terminated in December 2011 a
July 31, 2014	DEF 14A	RGRX / RegeneRx Biopharmaceuticals, Inc. DEF 14A - - DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) þ Definitive Proxy State
May 23, 2014	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2014 REGENERX BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-15070 52-1253406 (State or other jurisdiction of incorporation) (Com
May 23, 2014	EX-99.1	15245 Shady Grove Road Exhibit 99.1 15245 Shady Grove Road Suite 470 Rockville, MD 20850 301.208.9191 May 22, 2014 Dear Shareholder: We would like to update you on developments at RegeneRx over the past twelve months and advise you on our strategy through 2015. We accomplished several important goals this past year despite significant financial constraints. We are pleased that during this period, members of management a
May 15, 2014	EX-10.5	Exhibit 10.5 to Quarterly Report on Form10-Q (File No. 001-15070) (filed May 15, 2014) Exhibit 10.5 SECURITIES PURCHASE AGREEMENT Dated as of March 7, 2014 Between REGENERX BIOPHARMACEUTICALS, INC. and DIGITAL ARIA CO., LTD. Table of Contents Page SECTION 1. DEFINITIONS 1 SECTION 2. ISSUANCE AND SALE OF THE SHARES 3 SECTION 3. THE CLOSING 3 3.1 Closing 3 3.2 Deliveries by the Company 4 3.3 Deliveries by the Investor 5 SECTION 4. REPRESENTATIONS, WARRANTIES AND COVENANTS 5 4.1 Repres
May 15, 2014	10-Q	United States Securities and Exchange Commission Washington, DC 20549 FORM 10-Q United States Securities and Exchange Commission Washington, DC 20549 FORM 10-Q ? Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2014 ? Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to .
May 15, 2014	EX-10.7	Exhibit 10.7 to Quarterly Report on Form10-Q (File No. 001-15070) (filed May 15, 2014) Exhibit 10.7 * text ommitted and filed seperately confidential treatment requested under 17 c.f.r.??200.80(b)(4) and 240.24b-2 rgn-137 LICENSE Agreement This License Agreement (this ?Agreement? or this ?License Agreement?) is effective as of March 7, 2014 (the ?Effective Date?) by and between RegeneRx Biopharmaceuticals, Inc., a company organized and existing under the laws of the state of Delaw
May 15, 2014	EX-10.6	Exhibit 10.6 to Quarterly Report on Form10-Q (File No. 001-15070) (filed May 15, 2014) Exhibit 10.6 * text ommitted and filed seperately confidential treatment requested under 17 c.f.r.??200.80(b)(4) and 240.24b-2 RGN-259 LICENSE Agreement This License Agreement (this ?Agreement? or this ?License Agreement?) is effective as of March 7, 2014 (the ?Effective Date?) by and between RegeneRx Biopharmaceuticals, Inc., a company organized and existing under the laws of the state of Delaw
April 22, 2014	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2014 REGENERX BIOPHARMACEUTICALS, INC.
April 4, 2014	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15070 RegeneRx Bioph
April 1, 2014	NT 10-K	- NT 10-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 001-15070 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 75886X108 (Check One): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR CUSIP NUMBER For Period Ended: December 31, 2013 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K
April 1, 2014	SC 13D/A	RGRX / RegeneRx Biopharmaceuticals, Inc. / G-treeBNT Co., Ltd. - SCHEDULE 13D/A 4-1-14 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D/A (Amendment No.
April 1, 2014	EX-7.01	SECURITIES PURCHASE AGREEMENT Dated as of March 7, 2014 REGENERX BIOPHARMACEUTICALS, INC. DIGITAL ARIA CO., LTD. Table of Contents SECURITIES PURCHASE AGREEMENT Dated as of March 7, 2014 Between REGENERX BIOPHARMACEUTICALS, INC.
March 17, 2014	SC 13D	RGRX / RegeneRx Biopharmaceuticals, Inc. / G-treeBNT Co., Ltd. - FORM SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.
March 11, 2014	EX-99.1	RegeneRx and Digital Aria Sign Product License and Stock Purchase Agreements Exhibit 99.1 RegeneRx Biopharmaceuticals Inc. 15245 Shady Grove Road, Suite 470 Rockville, Maryland 20850 PHONE 301.208.9191 FAX 301.208.9194 WEB www.regenerx.com News Release RegeneRx and Digital Aria Sign Product License and Stock Purchase Agreements ROCKVILLE, Md. (March 7, 2014) – RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) (“the Company” or “RegeneRx”) today announced that it has entered in
March 11, 2014	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Regulation FD Disclosure - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2014 REGENERX BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-15070 52-1253406 (State or other jurisdiction of incorporation) (Co
February 28, 2014	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2014 REGENERX BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-15070 52-1253406 (State or other jurisdiction of incorporation)
February 14, 2014	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2014 REGENERX BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-15070 52-1253406 (State or other jurisdiction of incorporation)
January 9, 2014	EX-10.2	Exhibit 10.2 to Current Report on Form 8-K (File No. 001-15070) (filed January 9, 2014) Exhibit 10.2 January 7, 2014 Mr. J.J. Finkelstein 3910 East-West Highway Chevy Chase, MD 20815 Re: Third Amendment to Temporary Employment Terms and to Amended and Restated Change in Control Agreement Dear J.J.: This letter agreement (the “Amendment”) amends certain of the terms and conditions relating to your employment with RegeneRx Biopharmaceuticals, Inc. (“Company”) that were set forth in tha
January 9, 2014	EX-4.1	Exhibit 4.1 to Current Report on Form 8-K (File No. 001-15070) (filed January 9, 2014) Exhibit 4.1 THIS CONVERTIBLE PROMISSORY NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN
January 9, 2014	EX-10.1	Exhibit 10.1 to Current Report on Form 8-K (File No. 001-15070) (filed January 9, 2014) Exhibit 10.1 REGENERX BIOPHARMACEUTICALS, INC. CONVERTIBLE NOTE PURCHASE AGREEMENT January 7, 2014 SECTION 1. DEFINITIONS 1 SECTION 2. ISSUANCE AND SALE OF THE SECURITIES 3 SECTION 3. THE CLOSING 3 3.1 Closing 3 3.2 Deliveries by the Company 3 3.3 Deliveries by the Investor 4 SECTION 4. REPRESENTATIONS, WARRANTIES AND COVENANTS 4 4.1 Representations and Warranties of the Company 4 4.2 Representati
January 9, 2014	EX-10.3	Exhibit 10.3 to Quarterly Report on Form10-Q (File No. 001-15070) (filed January 9, 2014) Exhibit 10.3 January 7, 2014 Dr. Allan L. Goldstein P.O. Box 29 Reedville, VA 22539 Re: Third Amendment to Temporary Employment Terms and to Amended and Restated Change in Control Agreement Dear Allan: This letter agreement (the “Amendment”) amends certain of the terms and conditions relating to your employment with RegeneRx Biopharmaceuticals, Inc. (“Company”) that were set forth in that Temporar
January 9, 2014	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Entry into a Material Definitive Agreement - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2014 REGENERX BIOPHARMACEUTICALS, INC.
December 23, 2013	SC 13D/A	RGRX / RegeneRx Biopharmaceuticals, Inc. / Essetifin Spa - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A19 (Amendment No. 19) Under the Securities Exchange Act of 1934 RegeneRx Biopharmaceuticals, Inc. (Name of Issuer) Common Stock, Par Value $0.001 per share (Title of Class of Securities) 020910105 (CUSIP Number) Brian B. Margolis, Esq. Orrick, Herrington & Sutcliffe LLP 51 West 52nd Street New York, NY 10019-6142 (212) 506-500
November 18, 2013	10-Q	Securities and Exchange Commission Washington, DC 20549 FORM 10-Q Securities and Exchange Commission Washington, DC 20549 FORM 10-Q þ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2013 ¨ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to .
November 15, 2013	NT 10-Q	- NT 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 001-15070 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 75886X108 (Check One): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR CUSIP NUMBER For Period Ended: September 30, 2013 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Repor
September 24, 2013	SC 13D/A	RGRX / RegeneRx Biopharmaceuticals, Inc. / CAVAZZA PAOLO - PAOLO CAVAZZA SCHEDULE 13D/A NO. 18 Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A18 (Amendment No. 18) Under the Securities Exchange Act of 1934 RegeneRx Biopharmaceuticals, Inc. (Name of Issuer) Common Stock, Par Value $0.001 per share (Title of Class of Securities) 020910105 (CUSIP Number) James Robinson, Esq. Cahill Gordon & Reindel llp 80 Pine Street New York, NY 10005 (212) 701-3000 (Name, Address and
September 24, 2013	SC 13D/A	RGRX / RegeneRx Biopharmaceuticals, Inc. / Taufin International S.A. - TAUFIN INTERNATIONAL S.A. SCHEDULE 13D/A NO. 18 Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A18 (Amendment No. 18) Under the Securities Exchange Act of 1934 RegeneRx Biopharmaceuticals, Inc. (Name of Issuer) Common Stock, Par Value $0.001 per share (Title of Class of Securities) 020910105 (CUSIP Number) James Robinson, Esq. Cahill Gordon & Reindel llp 80 Pine Street New York, NY 10005 (212) 701-3000 (Name, Address and
September 24, 2013	SC 13D/A	RGRX / RegeneRx Biopharmaceuticals, Inc. / DEFIANTE FARMACEUTICA LDA - DEFIANTE SCHEDULE 13D/A NO. 18 Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A18 (Amendment No. 18) Under the Securities Exchange Act of 1934 RegeneRx Biopharmaceuticals, Inc. (Name of Issuer) Common Stock, Par Value $0.001 per share (Title of Class of Securities) 020910105 (CUSIP Number) James Robinson, Esq. Cahill Gordon & Reindel llp 80 Pine Street New York, NY 10005 (212) 701-3000 (Name, Address and
September 24, 2013	SC 13D/A	RGRX / RegeneRx Biopharmaceuticals, Inc. / Sinaf S.a. - SINAF S.A. SCHEDULE 13D/A NO. 18 Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A18 (Amendment No. 18) Under the Securities Exchange Act of 1934 RegeneRx Biopharmaceuticals, Inc. (Name of Issuer) Common Stock, Par Value $0.001 per share (Title of Class of Securities) 020910105 (CUSIP Number) James Robinson, Esq. Cahill Gordon & Reindel llp 80 Pine Street New York, NY 10005 (212) 701-3000 (Name, Address and
September 24, 2013	SC 13D/A	RGRX / RegeneRx Biopharmaceuticals, Inc. / Essetifin Spa - SIGMA-TAU FINANZIARIA SCHEDULE 13D/A NO. 18 Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A18 (Amendment No. 18) Under the Securities Exchange Act of 1934 RegeneRx Biopharmaceuticals, Inc. (Name of Issuer) Common Stock, Par Value $0.001 per share (Title of Class of Securities) 020910105 (CUSIP Number) James Robinson, Esq. Cahill Gordon & Reindel llp 80 Pine Street New York, NY 10005 (212) 701-3000 (Name, Address and
September 17, 2013	EX-4.1	Exhibit 4.1 to Current Report on Form 8-K (File No. 001-15070) (filed September 19, 2013) Exhibit 4.1 THIS CONVERTIBLE PROMISSORY NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN
September 17, 2013	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2013 REGENERX BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-15070 52-1253406 (State or other jurisdiction of incorporation
September 17, 2013	EX-10.1	Exhibit 10.1 to Current Report on Form 8-K (File No. 001-15070) (filed September 19, 2013) Exhibit 10.1 REGENERX BIOPHARMACEUTICALS, INC. CONVERTIBLE NOTE PURCHASE AGREEMENT September 11, 2013 Table of Contents Page SECTION 1. DEFINITIONS 1 SECTION 2. ISSUANCE AND SALE OF THE SECURITIES 3 SECTION 3. THE CLOSING 3 3.1 Closing 3 3.2 Deliveries by the Company 3 3.3 Deliveries by the Investor 4 SECTION 4. REPRESENTATIONS, WARRANTIES AND COVENANTS 4 4.1 Representations and Warranties of the
August 14, 2013	10-Q	Securities and Exchange Commission Washington, DC 20549 FORM 10-Q Securities and Exchange Commission Washington, DC 20549 FORM 10-Q ? Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2013 ? Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to .
July 11, 2013	EX-10.2	Exhibit 10.2 to Current Report on Form 8-K (File No. 001-15070) (filed July 11, 2013) Exhibit 10.2 July 5, 2013 Mr. J.J. Finkelstein 3910 East-West Highway Chevy Chase, MD 20815 Re: Second Amendment to Temporary Employment Terms and to Amended and Restated Change in Control Agreement Dear J.J.: This letter agreement (the “Amendment”) amends certain of the terms and conditions relating to your employment with RegeneRx Biopharmaceuticals, Inc. (“Company”) that were set forth in that
July 11, 2013	EX-10.3	July 5, 2013 Exhibit 10.3 July 5, 2013 Mr. David R. Crockford 62 Kent Street Newburyport, MA 01950 Re: Second Amendment to Temporary Employment Terms and to Amended and Restated Change in Control Agreement Dear David: This letter agreement (the “Amendment”) amends certain of the terms and conditions relating to your employment with RegeneRx Biopharmaceuticals, Inc. (“Company”) that were set forth in that Tempo
July 11, 2013	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2013 REGENERX BIOPHARMACEUTICALS, INC.
July 11, 2013	EX-10.1	Exhibit 10.1 to Current Report on Form 8-K (File No. 001-15070) (filed July 11, 2013) Exhibit 10.1 REGENERX BIOPHARMACEUTICALS, INC. CONVERTIBLE NOTE PURCHASE AGREEMENT July 5, 2013 Table of Contents Page SECTION 1. DEFINITIONS 1 SECTION 2. ISSUANCE AND SALE OF THE SECURITIES 3 SECTION 3. THE CLOSING 3 3.1 Closing 3 3.2 Deliveries by the Company 4 3.3 Deliveries by the Investor 4 SECTION 4. REPRESENTATIONS, WARRANTIES AND COVENANTS 4 4.1 Representations and Warranties of the Compan
July 11, 2013	EX-4.1	Exhibit 4.1 to Current Report on Form 8-K (File No. 001-15070) (filed July 11, 2013) Exhibit 4.1 THIS CONVERTIBLE PROMISSORY NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN
July 11, 2013	EX-10.4	Exhibit 10.4 to Current Report on Form 8-K (File No. 001-15070) (filed July 11, 2013) Exhibit 10.4 July 5, 2013 Dr. Allan L. Goldstein P.O. Box 29 Reedville,Va 22539 Re: Second Amendment to Temporary Employment Terms and to Amended and Restated Change in Control Agreement Dear Allan: This letter agreement (the “Amendment”) amends certain of the terms and conditions relating to your employment with RegeneRx Biopharmaceuticals, Inc. (“Company”) that were set forth in that Temporary E
May 15, 2013	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2013 REGENERX BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-15070 52-1253406 (State or other jurisdiction of incorporation) (Com
May 15, 2013	10-Q	Securities and Exchange Commission Washington, DC 20549 FORM 10-Q þ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2013 ¨ Transition Report pursuant to Section 13 or 15 Securities and Exchange Commission Washington, DC 20549 FORM 10-Q þ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2013 ¨ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to .
May 15, 2013	EX-99.1	15245 Shady Grove Road Exhibit 99.1 15245 Shady Grove Road Suite 470 Rockville, MD 20850 301.208.9191 May 13, 2013 Dear Shareholder: We would like to update you on developments at RegeneRx over the past twelve months and advise you on our refined strategy for the coming year. Despite our difficulty in raising capital in a tough financial market for microcap biopharmaceutical companies, we have accomplished several impor
April 16, 2013	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K 10-K 1 v33747210k.htm FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file
April 3, 2013	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2013 REGENERX BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-15070 52-1253406 (State or other jurisdiction of incorporation) (C
April 3, 2013	EX-10.1	Exhibit 10.1 to Current Report on Form 8-K (File No. 001-15070) (filed April 2, 2013) Exhibit 10.1 REGENERX BIOPHARMACEUTICALS, INC. CONVERTIBLE NOTE PURCHASE AGREEMENT March 29, 2013 Table of Contents Page SECTION 1. DEFINITIONS 1 SECTION 2. ISSUANCE AND SALE OF THE SECURITIES 3 SECTION 3. THE CLOSING 3 3.1 Closing 3 3.2 Deliveries by the Company 3 3.3 Deliveries by the Investor 4 SECTION 4. REPRESENTATIONS, WARRANTIES AND COVENANTS 4 4.1 Representations and Warranties of the Comp
April 3, 2013	EX-99.1	RegeneRx Issues $225,000 Convertible Note Exhibit 99.1 RegeneRx Biopharmaceuticals Inc. 15245 Shady Grove Road, Suite 470 Rockville, Maryland20850 PHONE 301.208.9191 FAX 301.208.9194 WEB www.regenerx.com News Release RegeneRx Issues $225,000 Convertible Note ROCKVILLE, Md. (April 1, 2013) – RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) (“the Company” or “RegeneRx”) today announced that it has received $225,000 through the i
April 3, 2013	EX-4.1	Exhibit 4.1 to Current Report on Form 8-K (File No. 001-15070) (filed April 2, 2013) Exhibit 4.1 THIS CONVERTIBLE PROMISSORY NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN
April 2, 2013	NT 10-K	- NT 10-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 001-15070 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 75886X108 CUSIP NUMBER (Check One): x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: December 31, 2012 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report
January 16, 2013	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No.

RGRX / RegeneRx Biopharmaceuticals, Inc. - Depositi SEC, Relazione annuale, dichiarazione di delega

Statistiche di base

SEC Filings

SEC Filings (Chronological Order)